News file for: Vaccine
Singapore’s A*STAR and Switzerland’s Cytos Biotechnology AG today announced the initiation of Phase I trials for their H1N1 influenza vaccine candidate.
Researchers from Singapore and the U.S. have engineered a potent antibody against the dengue virus.
The World Health Organization has released a FAQ list answering some questions relating to the H7N9 influenza A virus outbreak in China.
Sanofi Pasteur and Xiamen University in China have agreed to jointly develop a universal flu vaccine.
An expert says that fresh estimates of the number of cases of dengue fever in South-East Asia and one country in South Asia are too low.
Takeda Pharma has submitted New Drug Applications for cell culture-based H5N1 influenza vaccines to the Ministry of Health, Labor and Welfare in Japan.
Chinese vaccine provider Sinovac Biotech Ltd. has completed a Phase III clinical trial on its Enterovirus 71 vaccine against hand, foot, and mouth disease.
Inviragen, Inc. has initiated the second stage of an ongoing Phase II study of DENVax™, its investigational dengue vaccine.
Researchers have designed a new drug to safeguard against epidemic and pandemic influenza virus strains.
Vietnam’s VABIOTECH has acquired rights to Inviragen’s proprietary Japanese encephalitis technology to produce a cell-derived vaccine.